Pioneering ion channel team, 1990
ABOUT US

Our History

Saniona Icon blue

Saniona was built on a foundation of more than 20 years of pioneering ion channel research

1

1989–2011

Leading ion channel scientific team established

Celebration in Glostrup with founding team members

2011

Saniona founded based on advanced ion channel discovery engine and compound library

2013

Saniona’s first spin-out, Ataxion.

Saniona advances preclinical GABA and K+ ion channel programs

2014

Saniona IPO in Stockholm.

Saniona’s compound library exceeds 1,000 compounds

2016

Saniona licenses tesofensine rights in Mexico and Argentina to Medix

2017

SAN711 selected for preclinical development.

Saniona spins out Scandion Oncology

Saniona compound library

2018

Positive Phase 2 data with Tesomet in Prader-Willi syndrome.

Proprietary compound library exceeds 20,000 compounds

2019

SAN903 selected for preclinical development

2020

Positive Phase 2 data with Tesomet in hypothalamic obesity

2021

Orphan Drug Designation in HO and PWS

Created capsule formulation for Tesomet

Initiated Phase 1 trial of SAN711

Initiated Phase 2b trial of Tesomet for hypothalamic obesity

Initiated Phase 2b trial of Tesomet for PWS

2022

Phase 1 study for SAN711 for neuropathic pain completed successfully making the program ready for Phase 2

Pre-clinical development program for SAN903 for inflammatory bowel disease completed successfully enabling Phase 1 studies in Europe

Kv7 program for epilepsy advanced into lead optimization

SAN2219 is selected as Preclinical Candidate for Epilepsy

2023

Saniona’s partner Medix receives a favorable opinion for tesofensine

Kv7 epilepsy compound is promoted to the candidate selection phase

SAN2355 is selected as a clinical candidate

2024

SAN2465 is selected as a clinical candidate for major depressive disorder